# Prostate Cancer and Prostatic Diseases

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/prostate-cancer-and-prostatic-diseases/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1365-7852 |
| ISSNs | 1365-7852,1476-5608 |
| OpenAlex ID | https://openalex.org/S107943385 |
| Publisher | Springer Nature |

## Journal papers

- [A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy](https://scholariq.org/papers/a-prospective-randomized-comparison-of-diagnostic-efficacy-between-transperineal/)
- [Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate](https://scholariq.org/papers/survival-outcomes-in-patients-with-chemotherapy-naive-metastatic-castration/)
- [A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer](https://scholariq.org/papers/a-retrospective-analysis-illustrating-the-substantial-clinical-and-economic/)
- [Low quality of life in men with chronic prostatitis-like symptoms](https://scholariq.org/papers/low-quality-of-life-in-men-with-chronic-prostatitis-like-symptoms/)
- [Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer](https://scholariq.org/papers/emerging-racial-disparities-among-medicare-beneficiaries-and-veterans-with/)
- [Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study](https://scholariq.org/papers/neoadjuvant-pamiparib-plus-abiraterone-and-androgen-deprivation-therapy-for-high/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.